1. Home
  2. PBHC vs LUNG Comparison

PBHC vs LUNG Comparison

Compare PBHC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pathfinder Bancorp Inc. (MD)

PBHC

Pathfinder Bancorp Inc. (MD)

HOLD

Current Price

$13.62

Market Cap

80.2M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.62

Market Cap

72.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBHC
LUNG
Founded
1859
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.2M
72.2M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
PBHC
LUNG
Price
$13.62
$1.62
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$6.81
AVG Volume (30 Days)
3.2K
365.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
2.92%
N/A
EPS Growth
46.25
10.00
EPS
0.47
N/A
Revenue
N/A
$83,789,000.00
Revenue This Year
N/A
$9.21
Revenue Next Year
N/A
$5.03
P/E Ratio
$29.03
N/A
Revenue Growth
N/A
22.01
52 Week Low
$12.06
$1.31
52 Week High
$17.00
$8.10

Technical Indicators

Market Signals
Indicator
PBHC
LUNG
Relative Strength Index (RSI) 49.51 51.24
Support Level $13.43 $1.51
Resistance Level $13.75 $1.69
Average True Range (ATR) 0.17 0.13
MACD 0.06 0.03
Stochastic Oscillator 87.40 56.94

Price Performance

Historical Comparison
PBHC
LUNG

About PBHC Pathfinder Bancorp Inc. (MD)

Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: